Desvenlafaxine

Desvenlafaxine

Clinical data
Trade names	Pristiq, Desfax, Ellefore
AHFS/Drugs.com	Monograph
MedlinePlus	a608022
License data	US FDA: Desvenlafaxine
Pregnancy category	AU: B2 US: C (Risk not ruled out)
Routes of administration	Oral
ATC code	N06AX23 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) CA: ℞-only US: ℞-only
Pharmacokinetic data
Bioavailability	80%
Protein binding	Low (30%)
Metabolism	CYP3A4, (CYP2D6 is not involved)
Biological half-life	11 h
Excretion	45% excreted unchanged in urine
Identifiers
IUPAC name 4-[2-dimethylamino-1-(1-hydroxycyclohexyl) ethyl]phenol
CAS Number	93413-62-8 Y
PubChem CID	125017
IUPHAR/BPS	7158
DrugBank	DB06700 Y
ChemSpider	111300 Y
UNII	NG99554ANW
KEGG	D07793 Y
ChEBI	CHEBI:83527 N
ChEMBL	CHEMBL1118 Y
ECHA InfoCard	100.149.615
Chemical and physical data
Formula	C16H25NO2
Molar mass	263.38 g/mol
3D model (Jmol)	Interactive image
SMILES OC2(C(c1ccc(O)cc1)CN(C)C)CCCCC2
InChI InChI=1S/C16H25NO2/c1-17(2)12-15(13-6-8-14(18)9-7-13)16(19)10-4-3-5-11-16/h6-9,15,18-19H,3-5,10-12H2,1-2H3 Y Key:KYYIDSXMWOZKMP-UHFFFAOYSA-N Y
NY (what is this?)

Desvenlafaxine (brand name: Pristiq, Desfax, Ellefore), also known as O-desmethylvenlafaxine, is an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI) class developed and marketed by Wyeth (now part of Pfizer). Desvenlafaxine is a synthetic form of the major active metabolite of venlafaxine (sold under the brand names Effexor and Efexor). It is being targeted as the first non-hormonal based treatment for menopause. It is an example of evergreening.

Desvenlafaxine's primary use in medicine is the treatment of major depressive disorder.

Adverse effect incidence

Very common (>10% incidence) adverse effects include:

Common (1-10% incidence) adverse effects include:

Uncommon (0.1-1% incidence) adverse effects include:

Rare (<0.1% incidence) adverse effects include:

Unknown frequency adverse effects include:

Desvenlafaxine is a synthetic form of the isolated major active metabolite of venlafaxine, and is categorized as a serotonin-norepinephrine reuptake inhibitor (SNRI). When most normal metabolizers take venlafaxine, approximately 70% of the dose is metabolized into desvenlafaxine, so the effects of the two drugs are expected to be very similar. It works by blocking the "reuptake" transporters for key neurotransmitters affecting mood, thereby leaving more active neurotransmitters in the synapse. The neurotransmitters affected are serotonin (5-hydroxytryptamine) and norepinephrine (noradrenaline). It is approximately 10 times more potent at inhibiting serotonin uptake than norepinephrine uptake.